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COST-EFFECTIVENESS OF TAMOXIFEN IN 
BREAST CANCER RISK REDUCTION
Sengupta N, Hay JW
Pharmaceutical Economics & Policy, University of Southern 
California, Los Angeles, CA, USA
OBJECTIVE: To determine the cost and cost-effective-
ness of tamoxifen for breast cancer risk reduction. Breast
cancer affects one of every nine American women.
Tamoxifen is the only drug approved by the US FDA for
breast cancer risk reduction. Little research has been
done on cost-effectiveness of this therapy. METHODS: A
cost-effectiveness analysis was used to evaluate the eco-
nomic impact of five-year preventive therapy with
tamoxifen. Data from a large randomized clinical trial
(National Surgical Adjuvant Breast and Bowel Project
P1) were used to develop this cost-effectiveness analysis.
Study participants were a hypothetical cohort of at-risk
US females between age 40 and 75 years. The analysis
was done from a societal perspective, using a 3% annual
discount rate. Health effects were measured by life year
saved and quality adjusted life year (QALY) gained from
the treatment. Cost-effectiveness results were determined
as incremental costs per QALY. RESULTS: Under the
base case assumptions, tamoxifen therapy increased ex-
pected average medical cost $16,838 over five years. The
net five-year average medical cost associated with ther-
apy was $27,365. Average discounted survival benefits
were 0.523 year of life and 0.384 QALY per participant.
This resulted in average cost-effectiveness ratios of
$32,195 per year of life and $43,848 per QALY saved.
Results of the model were relatively insensitive to reason-
able parameter changes. Tamoxifen therapy was substan-
tially more cost-effective for high-risk females ($22,459
per life year and $33,150 per quality adjusted life year).
CONCLUSIONS: The cost per QALY of tamoxifen in
patients at moderate and substantially elevated breast
cancer risk compares favorably with that for many other
standard medical interventions. Therefore, five-year tamox-
ifen therapy is a cost-effective approach for breast cancer
risk reduction.
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VALIDITY OF THE TIME-TRADE OFF 
TECHNIQUE IN DETERMINING PREFERENCES 
FOR THE TREATMENT OF PROSTATE CANCER
Watkins Bruner D, Baron J
Fox Chase Cancer Center, Cheltenham, PA, USA
Several cost-utility studies have shown little or no benefit
for the cost of screening or treatment of asymptomatic
prostate cancer. An important factor in these decision
analyses was subject preference/utility. Preference can be
defined as a subject’s contemplative first choice among a
series of alternatives. Utility is derived from the individ-
ual preferences for a condition or health state. Prefer-
ences are summed and the ensuing value is used to weight
survival or other health outcome. OBJECTIVE: This
study aimed to: 1) assess preferences for radiotherapy,
surgery, hormones, and observation for the treatment of
prostate cancer. METHODS: Fifty men, 25 with and 25
without prostate cancer, were interviewed, using the
Time Trade-Off (TTO) Technique. RESULTS: The men
in this study, regardless of group (cancer vs. no cancer),
showed an increased preference for surgery versus radio-
therapy or hormones, as compared to observation. This
presented logical inconsistencies, since surgery was pre-
sented with twice the risk of impotence and three times
the risk of incontinence as radiotherapy. The validity of
the TTO was therefore assessed by comparing predicted
to actual individual utility scores. For example, the utility
(U) a man placed on an 80% chance of impotence (IP80)
should be half the utility placed on a 40% chance of im-
potence (IP40), if men attended to probabilities of risk.
The observed mean IP80 utility was 0.7957 versus
0.6098 for the predicted (P  0.0002). Similar differ-
ences were found between predicted and observed utility
values for other probabilities of impotence and inconti-
nence. CONCLUSION: Threats to the validity of the
TTO have been documented. Imperfect as the TTO is, it
does provide a more objective process to the traditionally
subjective means by which decisions regarding health
care policy have been made. Therefore, the TTO requires
further testing and modifications to improve validity,
some of which are discussed in this presentation.
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CONVENIENCE IS THE MAIN REASON WHY 
OVARIAN CANCER PATIENTS PREFER 
ORAL REGIMEN
Calhoun EA, Roland PY
Northwestern University, Chicago, IL USA
OBJECTIVE: To examine patients’ preferences and be-
liefs about oral versus intravenous chemotherapy in re-
current ovarian cancer. Despite encouraging short-term
results, most patients ultimately develop recurrence. Sec-
ond-line treatment plays an important role in the care of
this patient population. Quality of life and patient prefer-
ences have not been well studied in this setting. METH-
ODS: Patients who have received 1st line IV therapy an-
swered an investigator-developed survey of ‘preferences
and beliefs regarding route of chemotherapy administration.
Patients rated statements from 1 (strongly agree) to 5
(strongly disagree). The willingness to accept additional
costs for oral chemotherapy was also surveyed. RE-
SULTS: Of 39 patients assessed, 56% stated a preference
for oral chemotherapy, 28% preferred IV chemotherapy,
and 15% had no preference. Interestingly, even patients
stating a preference for IV therapy were willing to pay an
average of $450 per cycle for oral chemotherapy. While
oral preference patients were willing to pay $687 out-of-
pocket per cycle of chemotherapy.
